文献速递浆细胞疾病

利用SKY92基因表达谱在真实世界数据中增强多发性骨髓瘤的风险分层与治疗决策

Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data.
PubMed 文献 · Br J Haematol · 2025-04-15

前瞻性观察性多发性骨髓瘤影响研究(NCT02911571)纳入251例新诊断多发性骨髓瘤患者,比较SKY92基因表达谱与常规标志物的风险分层一致性及对治疗决策的影响。初始临床风险评估与SKY92结果一致性差(高危:51% vs 28%,Cohen's κ=0.21)。SKY92对无进展生存和总生存的预测优于传统标志物(p≤0.0001),揭盲后50%患者假设治疗方案被修改(p<0.001),40%病例医生信心增加。

要点

  • SKY92与初始临床风险评估的高危比例分别为28%和51%,一致性差(Cohen's κ=0.21)。
  • SKY92对无进展生存和总生存的预测优于传统风险标志物(p≤0.0001)。
  • 揭盲SKY92后50%患者假设治疗方案修改(p<0.001),40%病例医生治疗决策信心增加。

核心结论

  • SKY92在识别高危多发性骨髓瘤患者方面具有预后价值,优于传统风险标志物,并显示出整合到临床实践以实现更个性化风险评估的潜在附加价值。

研究设计与样本

  • 前瞻性观察性多发性骨髓瘤影响研究(PRospective Observational Multiple Myeloma Impact Study,NCT02911571),纳入251例新诊断多发性骨髓瘤患者。
  • 医生在揭盲SKY92结果前后填写问卷,记录风险分类、假设治疗方案及对方案的信心。

主要发现

  • 初始临床风险评估与SKY92结果一致性差:高危患者比例初始临床风险评估为51%,SKY92为28%,Cohen's κ=0.21。
  • SKY92在识别高危患者方面表现更优,对无进展生存和总生存的预测优于传统风险标志物(p≤0.0001)。
  • 揭盲SKY92结果后,50%患者的假设治疗方案被修改(p<0.001),40%病例医生对治疗决策的信心增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the years, numerous prognostic markers for multiple myeloma (MM) risk classification have been identified; however, their variability can lead to inconsistent clinical interpretations. Gene expression profiling (GEP) signatures, such as SKY92, offer a more accurate method for patient stratification. The PRospective Observational Multiple Myeloma Impact Study (NCT02911571) aimed to validate SKY92's prognostic performance using real-world data and assess its impact on risk classification and treatment decisions compared to conventional markers. In a study of 251 newly diagnosed MM patients, physicians completed questionnaires to capture risk classification, hypothetical treatment plans and their confidence in those plans before and after unblinding SKY92 results. Poor concordance was observed between initial clinical risk assessment (iCRA) and SKY92 results (high risk: 51% iCRA vs. 28% SKY92, Cohen's κ = 0.21). SKY92 showed superior performance in identifying high-risk patients, leading to better predictions of progression-free survival and overall survival (p ≤ 0.0001) than traditional risk markers. Unblinding SKY92 results led to hypothetical treatment revisions for 50% of patients (p < 0.001) and increased physicians' confidence in treatment decisions for 40% of cases. These findings support SKY92's prognostic value in identifying high-risk MM patients, outperforming traditional risk markers and demonstrating the potential added value of its integration into clinical practice for more personalized risk assessment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Biran N, Dhakal B, Niesvizky R, et al. Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data. Br J Haematol. 2025. PMID: 40231946. doi:10.1111/bjh.20050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。